Vir Biotechnology Valuation Multiples

Vir Biotechnology Overview

About Vir Biotechnology

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Founded

2016

HQ

Employees

367

Website

vir.bio

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $88M

EBITDA: ($419M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Vir Biotechnology Financials

Vir Biotechnology reported last 12-month revenue of $88M and negative EBITDA of ($419M).

In the same LTM period, Vir Biotechnology generated $84M in gross profit, ($419M) in EBITDA losses, and had net loss of ($409M).

Vir Biotechnology P&L

In the most recent fiscal year, Vir Biotechnology reported revenue of $69M and EBITDA of ($455M).

Vir Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX

Vir Biotechnology Stock Performance

Vir Biotechnology has current market cap of $2B, and enterprise value of $1B.

Vir Biotechnology's stock price is $9.50.

Vir Biotechnology Valuation Multiples

Vir Biotechnology trades at 13.1x EV/Revenue multiple, and (2.7x) EV/EBITDA.

Vir Biotechnology Financial Valuation Multiples

As of April 11, 2026, Vir Biotechnology has market cap of $2B and EV of $1B.

Equity research analysts estimate Vir Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vir Biotechnology has a P/E ratio of (3.7x).

Vir Biotechnology Margins & Growth Rates

Vir Biotechnology's revenue in the last 12 month grew by 43%.

Vir Biotechnology's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.5M for the same period.

Vir Biotechnology's rule of 40 is (126%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vir Biotechnology's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Vir Biotechnology Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Vir Biotechnology M&A Activity

Vir Biotechnology acquired XXX companies to date.

Last acquisition by Vir Biotechnology was on XXXXXXXX, XXXXX. Vir Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Vir Biotechnology Investment Activity

Vir Biotechnology invested in XXX companies to date.

Vir Biotechnology made its latest investment on XXXXXXXX, XXXXX. Vir Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).